AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.6 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter to the Editor | Open Access

The Role of Glucose Transporter 1 in Drug Delivery: Transporter, Receptor and/or Signaling Component

Shiva Mehran1Zafar Gholinejad2( )
Department of Biology, Higher Education Institute of Rabe-Rashidi, Tabriz, Iran
Department of Medical Laboratory Science, Urmia Branch, Islamic Azad University, Urmia, Iran
Show Author Information

Abstract

The targeting of cell surface molecules is a promising strategy in drug delivery. Glucose modified-nanocarrier interacts with glucose transporter 1 (GLUT1) as a target molecule and increases nanocarrier-drug internalization to cancer and brain endothelial cells. The mechanism by which GLUT1 promotes nanocarrier internalization remains unclear. Herein, we propose that the interaction of GLUT1 and nanocarrier absorbs and traps the nanocarrier and simultaneously activates cell signaling pathways that is responsible for activation of the endocytosis system.

References

[1]

S. Azzi, J.K. Hebda, and J. Gavard, Vascular permeability and drug delivery in cancers. Front Oncol, 2013, 3: 211.

[2]

R. Bazak, Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Molecular and Clinical Oncology, 2014, 2(6): 904-908.

[3]

T.D. Clemons, Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy. Langmuir, 2018, 34(50): 15343-15349.

[4]

N. Muhamad, T. Plengsuriyakarn, and K. Na-Bangchang, Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. International Journal of Nanomedicine, 2018, 13: 3921.

[5]

R. Bazak, Cancer active targeting by nanoparticles: a comprehensive review of literature. Journal of Cancer Research and Clinical Oncology, 2015, 141(5): 769-784.

[6]

S.C. Pacheco-Velazquez, Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype. Mol Pharm, 2018, 15(6): 2151-2164.

[7]

K. Adekola, S.T. Rosen, and M. Shanmugam, Glucose transporters in cancer metabolism. Current Opinion in Oncology, 2012, 24(6): 650-654.

[8]

C.D. Young, Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res, 2008, 10(4): R70.

[9]

D. Avanzato, High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis. Cancer Res, 2018, 78(13): 3432-3444.

[10]

R. Roy, AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells. Mol Carcinog, 2019.

[11]

J.K. Blayney, Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget, 2018, 9(26): 18518-18528.

[12]

G.M.K. GabAllah, Validity and clinical impact of glucose transporter 1 expression in colorectal cancer. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association, 2017, 23(6): 348-356.

[13]

R. Gromnicova, Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One, 2013, 8(12): e81043.

[14]

L. Zhang, Preparation and characterization of GLUT1-mediated novel brain targeting magnetic nanoparticles. Letters in Drug Design & Discovery, 2018, 15(12): 1308-1313.

[15]

J. Li, Glucose-conjugated chitosan nanoparticles for targeted drug delivery and their specific interaction with tumor cells. Frontiers of Materials Science, 2014, 8(4): 363-372.

[16]

A. Salas-Burgos, Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: Insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J, 2004, 87(5): 2990-2999.

[17]

L. Venturelli, Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep, 2016, 6: 21629.

[18]

L. Kou, Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Frontiers in Pharmacology, 2018, 9: 27.

[19]

S. Oh, Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. BMB Rep, 2017, 50(3): 132-137.

[20]

L.E. Johannessen, Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 cells conditionally defective in clathrin-dependent endocytosis. Exp Cell Res, 2000, 260(1): 136-145.

[21]

X. Wu, FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell, 2005, 9(2): 185-196.

[22]

L. Han, Inhibitory effect of phloretin on alpha-glucosidase: Kinetics, interaction mechanism and molecular docking. Int J Biol Macromol, 2017, 95: 520-527.

[23]

A. Takeno, Phloretin promotes adipogenesis via mitogen-activated protein kinase pathways in mouse marrow stromal ST2 cells. International Journal of Molecular Sciences, 2018, 19(6): 1772.

[24]

K.R. Laderoute, 5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors. The Journal of Biological Chemistry, 2014, 289(33): 22850-22864.

[25]

B.M. Rezk, The antioxidant activity of phloretin: The disclosure of a new antioxidant pharmacophore in flavonoids. Biochem Biophys Res Commun, 2002, 295(1): 9-13.

[26]

Z. Gholinejad, N-acetyl cysteine and metal nanoparticles internalization: A critical methodological aspect. Journal of Bionanoscience, 2018, 12(5): 700-704.

[27]

J. Shi, Endothelial cell injury and dysfunction induced by silver nanoparticles through oxidative stress via IKK/NF-kappaB pathways. Biomaterials, 2014, 35(24): 6657-6666.

[28]

D. Barbaro, Glucose-coated superparamagnetic iron oxide nanoparticles prepared by metal vapour synthesis are electively internalized in a pancreatic adenocarcinoma cell line expressing GLUT1 transporter. PloS One, 2015, 10(4): e0123159-e0123159.

[29]

A.M. Master, A. Sen Gupta, EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine, 2012, 7(12): 1895-1906.

[30]

A. Tomas, C.E. Futter, and E.R. Eden, EGF receptor trafficking: Consequences for signaling and cancer. Trends in Cell Biology, 2014, 24(1): 26-34.

Nano Biomedicine and Engineering
Pages 347-350
Cite this article:
Mehran S, Gholinejad Z. The Role of Glucose Transporter 1 in Drug Delivery: Transporter, Receptor and/or Signaling Component. Nano Biomedicine and Engineering, 2019, 11(4): 347-350. https://doi.org/10.5101/nbe.v11i4.p347-350

530

Views

20

Downloads

0

Crossref

0

Scopus

Altmetrics

Received: 22 August 2019
Accepted: 14 November 2019
Published: 14 November 2019
© Shiva Mehran, Zafar Gholinejad.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return